LICENSE REVENUES - Narrative (Details)	1 Months Ended		3 Months Ended			9 Months Ended
	Nov. 30, 2024 USD ($)	May 31, 2024 USD ($)	Sep. 30, 2025 USD ($)	Jun. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) obligation	Sep. 30, 2024 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2020 program
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Total revenue			$ 0		$ 0	$ 1,300,000	$ 100,000
Nonrefundable, payment			1,300,000	$ 1,300,000
Maximum potential milestone payments			$ 41,250,000			$ 41,250,000
Revenue, number of performance obligation, | obligation						1
Amount allocated to performance obligation				$ 1,300,000
License Fee Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Total revenue						$ 1,300,000	100,000
Scithera License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Nonrefundable, payment						1,300,000
Scithera License Agreement | License Fee Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Revenue recognized related to performance obligation						1,300,000
2seventy bio, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Development milestone payment receivable								$ 51,500,000
2seventy bio, Inc. | Initial Programs
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Number of program related to collaborative agreement | program									2
2seventy bio, Inc. | Additional Programs
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Number of program related to collaborative agreement | program									8
Regeneron Pharmaceuticals, Inc. | Initial Programs, Program 3
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Nonrefundable, upfront payment	$ 100,000	$ 100,000
Nonrefundable, upfront payment, period (in months)	6 months
Regeneron Pharmaceuticals, Inc. | License Fee Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items
Total revenue						$ 0	$ 100,000